AstraZeneca (AZN) Q3 FY25 earnings call

AstraZeneca is converting an exceptional Phase III success rate into an early-stage-disease expansion thesis across oncology (Enhertu, Datroway, Imfinzi), cardiorenal (baxdrostat) and rare disease, while defending margins against LOE erosion in Brilinta and Farxiga and absorbing a US pricing settlement it insists leaves the 2030 ambition intact. The story is catalyst breadth, not a single quarter's print.